241 related articles for article (PubMed ID: 29069663)
1. Specific Adoptive Cellular Immunotherapy in Allogeneic Stem Cell Transplantation.
Audehm S; Krackhardt AM
Oncol Res Treat; 2017; 40(11):691-696. PubMed ID: 29069663
[TBL] [Abstract][Full Text] [Related]
2. T-cell-based Immunotherapies for Haematological Cancers, Part B: A SWOT Analysis of Adoptive Cell Therapies.
Rallis KS; Hillyar CRT; Sideris M; Davies JK
Anticancer Res; 2021 Mar; 41(3):1143-1156. PubMed ID: 33788705
[TBL] [Abstract][Full Text] [Related]
3. Adoptive Immunotherapies After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies.
Xiong Y; Bensoussan D; Decot V
Transfus Med Rev; 2015 Oct; 29(4):259-67. PubMed ID: 26282736
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies.
Liu J; Zhong JF; Zhang X; Zhang C
J Hematol Oncol; 2017 Jan; 10(1):35. PubMed ID: 28143567
[TBL] [Abstract][Full Text] [Related]
5. Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT.
Neuenhahn M; Albrecht J; Odendahl M; Schlott F; Dössinger G; Schiemann M; Lakshmipathi S; Martin K; Bunjes D; Harsdorf S; Weissinger EM; Menzel H; Verbeek M; Uharek L; Kröger N; Wagner E; Kobbe G; Schroeder T; Schmitt M; Held G; Herr W; Germeroth L; Bonig H; Tonn T; Einsele H; Busch DH; Grigoleit GU
Leukemia; 2017 Oct; 31(10):2161-2171. PubMed ID: 28090089
[TBL] [Abstract][Full Text] [Related]
6. Purification of CD4+ T cells for adoptive immunotherapy after allogeneic hematopoietic stem cell transplantation.
Klyuchnikov E; Sputtek A; Slesarchuk O; Lioznov M; Stübig T; Bacher U; Amtsfeld G; Merle E; Reckhaus ML; Fehse B; Wolschke C; Adjallé R; Ayuk F; Zander A; Kröger N
Biol Blood Marrow Transplant; 2011 Mar; 17(3):374-83. PubMed ID: 20637880
[TBL] [Abstract][Full Text] [Related]
7. A promising sword of tomorrow: Human γδ T cell strategies reconcile allo-HSCT complications.
Hu Y; Cui Q; Luo C; Luo Y; Shi J; Huang H
Blood Rev; 2016 May; 30(3):179-88. PubMed ID: 26654098
[TBL] [Abstract][Full Text] [Related]
8. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
9. Adoptive immunotherapy with genetically modified lymphocytes in allogeneic stem cell transplantation.
Cieri N; Mastaglio S; Oliveira G; Casucci M; Bondanza A; Bonini C
Immunol Rev; 2014 Jan; 257(1):165-80. PubMed ID: 24329796
[TBL] [Abstract][Full Text] [Related]
10. Cellular adoptive immunotherapy after autologous and allogeneic hematopoietic stem cell transplantation.
Porter DL; Hexner EO; Cooley S; Miller JS
Cancer Treat Res; 2009; 144():497-537. PubMed ID: 19779876
[No Abstract] [Full Text] [Related]
11. The expanding horizon of immunotherapy in the treatment of malignant disorders: allogeneic hematopoietic stem cell transplantation and beyond.
Tsirigotis P; Shimoni A; Nagler A
Ann Med; 2014 Sep; 46(6):384-96. PubMed ID: 24888385
[TBL] [Abstract][Full Text] [Related]
12. The roles of stem cell memory T cells in hematological malignancies.
Xu L; Zhang Y; Luo G; Li Y
J Hematol Oncol; 2015 Oct; 8():113. PubMed ID: 26462561
[TBL] [Abstract][Full Text] [Related]
13. The Potential Role of the Intestinal Micromilieu and Individual Microbes in the Immunobiology of Chimeric Antigen Receptor T-Cell Therapy.
Schubert ML; Rohrbach R; Schmitt M; Stein-Thoeringer CK
Front Immunol; 2021; 12():670286. PubMed ID: 34135898
[TBL] [Abstract][Full Text] [Related]
14. Defining success with cellular therapeutics: the current landscape for clinical end point and toxicity analysis.
Kean LS
Blood; 2018 Jun; 131(24):2630-2639. PubMed ID: 29728399
[TBL] [Abstract][Full Text] [Related]
15. Chimerism-based pre-emptive immunotherapy with fast withdrawal of immunosuppression and donor lymphocyte infusions after allogeneic stem cell transplantation for pediatric hematologic malignancies.
Horn B; Petrovic A; Wahlstrom J; Dvorak CC; Kong D; Hwang J; Expose-Spencer J; Gates M; Cowan MJ
Biol Blood Marrow Transplant; 2015 Apr; 21(4):729-37. PubMed ID: 25644958
[TBL] [Abstract][Full Text] [Related]
16. Cellular Immunotherapy for Hematologic Malignancies: Beyond Bone Marrow Transplantation.
Cirillo M; Tan P; Sturm M; Cole C
Biol Blood Marrow Transplant; 2018 Mar; 24(3):433-442. PubMed ID: 29102721
[TBL] [Abstract][Full Text] [Related]
17. Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort on Behalf of the Grupo Español de Trasplante Hematopoyetico.
Orti G; Sanz J; Bermudez A; Caballero D; Martinez C; Sierra J; Cabrera Marin JR; Espigado I; Solano C; Ferrà C; García-Noblejas A; Jimenez S; Sampol A; Yañez L; García-Gutiérrez V; Pascual MJ; Jurado M; Moraleda JM; Valcarcel D; Sanz MA; Carreras E; Duarte RF
Biol Blood Marrow Transplant; 2016 Mar; 22(3):584-8. PubMed ID: 26631751
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy following hematopoietic stem cell transplantation: potential for synergistic effects.
Bouchlaka MN; Redelman D; Murphy WJ
Immunotherapy; 2010 May; 2(3):399-418. PubMed ID: 20635904
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic immunotherapy to optimize the graft-versus-tumor effect: concepts and controversies.
Goldstein SC; Porter DL
Expert Rev Hematol; 2010 Jun; 3(3):301-14. PubMed ID: 21082981
[TBL] [Abstract][Full Text] [Related]
20. The in vitro generation of multi-tumor antigen-specific cytotoxic T cell clones: Candidates for leukemia adoptive immunotherapy following allogeneic stem cell transplantation.
Mohamed YS; Bashawri LA; Vatte C; Abu-Rish EY; Cyrus C; Khalaf WS; Browning MJ
Mol Immunol; 2016 Sep; 77():79-88. PubMed ID: 27490939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]